APA (7th ed.) Citation

Shibuki, T., Mizuta, T., Shimokawa, M., Koga, F., Ueda, Y., Nakazawa, J., . . . Otsuka, T. (2022). Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study). BMC Cancer, 22(1), 1. https://doi.org/10.1186/s12885-021-09139-y

Chicago Style (17th ed.) Citation

Shibuki, Taro, et al. "Prognostic Nomogram for Patients with Unresectable Pancreatic Cancer Treated with Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX: A Post-hoc Analysis of a Multicenter Retrospective Study in Japan (NAPOLEON Study)." BMC Cancer 22, no. 1 (2022): 1. https://doi.org/10.1186/s12885-021-09139-y.

MLA (9th ed.) Citation

Shibuki, Taro, et al. "Prognostic Nomogram for Patients with Unresectable Pancreatic Cancer Treated with Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX: A Post-hoc Analysis of a Multicenter Retrospective Study in Japan (NAPOLEON Study)." BMC Cancer, vol. 22, no. 1, 2022, p. 1, https://doi.org/10.1186/s12885-021-09139-y.